Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, has raised €12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as technology partner and existing investors, Takeda Ventures and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government. The proceeds from the financing will enable Enzyre to further develop its unique diagnostic technology platform, EnzyPad, which will enable hemophilia patients to determine and monitor their coagulation status from home in real-time. Olym advised Enzyre in this funding round.